Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2656 to 2670 of 9035 results

  1. Gilteritinib + daunorubicin + cytarabine for Acute myeloid leukaemia (AML) [TSID12331]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Epcoritamab + R-CHOP for Diffuse large B-cell lymphoma (DLBCL) [TSID12334]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Oesophageal String Test

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  4. High intensity focused electromagnetic (HIFEM) energy to target the pelvic floor muscles

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  5. LIVERFASt for diagnosing and staging liver injury and chronic liver disease, (MT783)

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  6. Epilepsies in children, young people and adults

    In development Reference number: GID-NG10453 Expected publication date:  05 August 2026

    NICE guideline
    In development

  7. Prostate cancer: diagnosis and management (update)

    In development Reference number: GID-NG10451 Expected publication date:  17 December 2027

    NICE guideline
    In development

  8. Zanubrutinib with rituximab for untreated mantle cell lymphoma when a stem cell transplant is unsuitable [ID6641]

    Awaiting development Reference number: GID-TA11843 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Radium-223 dichloride with enzalutamide for treating asymptomatic or mildly symptomatic hormone-relapsed metastatic prostate cancer with bone metastases [ID6512]

    Awaiting development Reference number: GID-TA11657 Expected publication date:  07 April 2027

    Technology appraisal guidance
    Awaiting development

  10. Durvalumab with radiotherapy for treating unresected node-negative stage 1 or 2 non-small-cell lung cancer [ID6567]

    Awaiting development Reference number: GID-TA11747 Expected publication date:  14 April 2027

    Technology appraisal guidance
    Awaiting development

  11. Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]

    In development Reference number: GID-TA11669 Expected publication date:  03 September 2026

    Technology appraisal guidance
    In development

  12. Obsessive-compulsive disorder and body dysmorphic disorder: assessment and management

    In development Reference number: GID-NG10435 Expected publication date:  16 February 2027

    NICE guideline
    In development

  13. Aprocitentan for treating resistant hypertension [ID6681]

    Awaiting development Reference number: GID-TA11459 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Ondansetron for treating alcohol-use disorder [ID6341]

    Awaiting development Reference number: GID-TA11375 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Epilepsies in children, young people and adults (extraordinary review)

    In development Reference number: GID-NG10378 Expected publication date: TBC

    NICE guideline
    In development